Lupeng Pharmaceutical recently completed 170 million yuan in its Series A+ round of financing. This round was led by Lilly Asia Ventures, with participation from existing investors FC Capital, TF Capital and other institutions.
Having participated in Lupeng Pharmaceutical's seed round since its inception, Kaitai Capital continues to inject cash in this round of financing as an existing investor of the company.
Established in June 2018, Lupeng Pharmaceutical is primarily involved in the development of innovative drugs for the treatment of severe diseases such as tumors, hepatitis B, autoimmunity and other diseases that seriously affect human health.
The company’s core pipeline LP-108 (selective BCL-2 inhibitor) has been approved for clinical stage in China and the United States.
Proceeds from this round of financing will be mainly used for the clinical study of LP-108, a selective BCL-2 inhibitor, as well as the development of several subsequent projects.